AR124957A2 - MODIFIED HINGE ANTIBODY FRAGMENTS AND METHODS OF PREPARATION THEREOF - Google Patents
MODIFIED HINGE ANTIBODY FRAGMENTS AND METHODS OF PREPARATION THEREOFInfo
- Publication number
- AR124957A2 AR124957A2 ARP220100392A ARP220100392A AR124957A2 AR 124957 A2 AR124957 A2 AR 124957A2 AR P220100392 A ARP220100392 A AR P220100392A AR P220100392 A ARP220100392 A AR P220100392A AR 124957 A2 AR124957 A2 AR 124957A2
- Authority
- AR
- Argentina
- Prior art keywords
- antibody fragment
- antibody fragments
- composition
- methods
- preparation
- Prior art date
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente revelación proporciona fragmentos de anticuerpos (por ej., Fab y F(ab)₂) que tienen una reactividad reducida o nula hacia anticuerpos anti bisagra (AHA) preexistentes y composiciones que comprenden tales fragmentos de anticuerpos, así como también métodos de fabricación y uso de tales fragmentos de anticuerpos y composiciones. Reivindicación 1: Una composición que comprende un fragmento de anticuerpo aislado, caracterizada porque el fragmento de anticuerpo tiene una reactividad reducida o nula frente a anticuerpos anti-bisagra preexistentes. Reivindicación 18: Una composición caracterizada porque comprende un ácido nucleico aislado que codifica el fragmento de anticuerpo de acuerdo con la reivindicación 1. Reivindicación 19: Una célula huésped caracterizada porque comprende la composición de acuerdo con la reivindicación 18. Reivindicación 20: Un método para la producción de un fragmento de anticuerpo caracterizado porque comprende el cultivo de la célula huésped de acuerdo con la reivindicación 19 de manera tal que se produzca el fragmento de anticuerpo. Reivindicación 21: Una formulación farmacéutica caracterizada porque comprende la composición de cualquiera de las reivindicaciones 1 a 17 y un portador aceptable para uso farmacéutico.The present disclosure provides antibody fragments (eg, Fab and F(ab)₂) that have little or no reactivity toward pre-existing anti-hinge antibodies (AHAs) and compositions comprising such antibody fragments, as well as methods of manufacture and use of such antibody fragments and compositions. Claim 1: A composition comprising an isolated antibody fragment, characterized in that the antibody fragment has little or no reactivity against pre-existing anti-hinge antibodies. Claim 18: A composition characterized in that it comprises an isolated nucleic acid encoding the antibody fragment according to claim 1. Claim 19: A host cell characterized in that it comprises the composition according to claim 18. Claim 20: A method for the production of an antibody fragment characterized in that it comprises culturing the host cell according to claim 19 in such a way that the antibody fragment is produced. Claim 21: A pharmaceutical formulation characterized in that it comprises the composition of any of claims 1 to 17 and a carrier acceptable for pharmaceutical use.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248792P | 2015-10-30 | 2015-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124957A2 true AR124957A2 (en) | 2023-05-24 |
Family
ID=61159892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103308A AR106524A1 (en) | 2015-10-30 | 2016-10-28 | FRAGMENTS OF ANTIBODIES WITH MODIFIED HINGE AND METHODS OF PREPARATION OF THE SAME |
| ARP220100392A AR124957A2 (en) | 2015-10-30 | 2022-02-23 | MODIFIED HINGE ANTIBODY FRAGMENTS AND METHODS OF PREPARATION THEREOF |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103308A AR106524A1 (en) | 2015-10-30 | 2016-10-28 | FRAGMENTS OF ANTIBODIES WITH MODIFIED HINGE AND METHODS OF PREPARATION OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR106524A1 (en) |
-
2016
- 2016-10-28 AR ARP160103308A patent/AR106524A1/en unknown
-
2022
- 2022-02-23 AR ARP220100392A patent/AR124957A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR106524A1 (en) | 2018-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019007369A2 (en) | anti-lag-3 antibodies and methods of use | |
| ECSP20024555A (en) | SPECIFIC ANTIBODIES FOR CD47 AND PD-L1 | |
| BR112017025564B8 (en) | Anti-ctla-4 antibodies and methods of using them | |
| BR112018074463A2 (en) | anti-tim-3 antibodies and methods of use. | |
| CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| CO2018012415A2 (en) | Specific binding proteins and uses thereof | |
| BR112019007288A2 (en) | bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient | |
| BR112018006350A2 (en) | antibodies, polynucleotide, vector, host cell, method for producing antibody, pharmaceutical formulation and use of antibody | |
| PE20210107A1 (en) | ANTI-CD3 ANTIBODIES AND METHODS OF USE | |
| BR112018003186A2 (en) | anti-pd-1 antibodies and their methods of use | |
| BR112018005164A2 (en) | antibodies, nucleic acid, host cell, method for producing an antibody, pharmaceutical formulation, use of the antibody and method of treating an individual who has cancer | |
| BR112016013347A8 (en) | anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof. | |
| BR112016010706A2 (en) | bispecific antibody, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, host cell and method of producing an antibody | |
| CL2021000028A1 (en) | Multispecific antibody (divisional application 937-2020). | |
| MY176822A (en) | Anti-pd-1 antibody and use thereof | |
| BR112015030946A8 (en) | composition comprising a non-native pancreatic ß cell, method of differentiating progenitor cells into pancreatic ß cells in vitro and use of a non-native pancreatic ß cell | |
| AR115389A1 (en) | CD73 ANTAGONIST ANTIBODY | |
| AU2014247175A8 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
| CO2017011238A2 (en) | Humanized anti-c1s antibodies | |
| BR112015030356A2 (en) | methods of treatment of a taupathy | |
| PE20160528A1 (en) | ANTIBODIES | |
| BR112016017764A2 (en) | broad spectrum antidengue antibody | |
| AR090668A1 (en) | ANTI-ADAMTS-5 ANTIBODY, DERIVATIVES AND USES OF THE SAME | |
| CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
| AR100944A1 (en) | INTERFERON ANTAGONIST ANTIBODIES a Y w |